Goldman, Naomi
Chandra, Aditi http://orcid.org/0000-0001-5313-9418
Johnson, Isabelle http://orcid.org/0009-0006-0357-6832
Sullivan, Matthew A. http://orcid.org/0000-0003-3651-0478
Patil, Abhijeet R. http://orcid.org/0000-0003-1444-1555
Vanderbeck, Ashley
Jay, Atishay
Zhou, Yeqiao
Ferrari, Emily K. http://orcid.org/0000-0002-1453-9432
Mayne, Leland
Aguilan, Jennifer
Xue, Hai-Hui http://orcid.org/0000-0002-9163-7669
Faryabi, Robert B. http://orcid.org/0000-0002-7931-2175
John Wherry, E. http://orcid.org/0000-0003-0477-1956
Sidoli, Simone
Maillard, Ivan http://orcid.org/0000-0003-1312-6748
Vahedi, Golnaz http://orcid.org/0000-0002-2249-8247
Funding for this research was provided by:
Burroughs Wellcome Fund
Article History
Received: 11 October 2022
Accepted: 20 July 2023
First Online: 17 August 2023
Competing interests
: E.J.W. is a member of the Parker Institute for Cancer Immunotherapy that supports research in the laboratory of E.J.W. E.J.W. is an advisor for Danger Bio, Marengo, Janssen, NewLimit, Pluto Immunotherapeutics Related Sciences, Santa Ana Bio, Synthekine and Surface Oncology. E.J.W. is a founder of and holds stock in Surface Oncology, Danger Bio and Arsenal Biosciences. The other authors declare no competing interests.